Internal Medicine, Hematology & Oncology · Live Oak, TX
NPI
1750392908
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
12602 Toepperwein Rd Ste 114
Live Oak, TX, 78233
Phone (210) 655-0075
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.1M
90,665 services
Medicare patients, 2024
688
Average age 75
Drug cost, 2024
$10.8M
2,316 prescriptions
Company payments, 2025
$7,584
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rohit Kapoor was code J9271 (injection, pembrolizumab, 1 mg), 20,400 times for 16 patients. In total Rohit Kapoor billed 90,665 services in 93 codes, and Medicare paid $2.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-02-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 20,400 | 16 | $44.58 | $909K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 6,610 | 68 | $0.23 | $1,547 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,150 | 48 | $0.08 | $351 |
| 36415 Venipuncture Blood Collection | Office | 2,526 | 544 | $8.58 | $22K |
| 85027 Blood Count | Office | 2,447 | 536 | $6.11 | $15K |
| 99213 Office E&M - Established | Office | 1,284 | 442 | $61.68 | $79K |
| 96367 Intravenous Infusion, Hydration | Office | 1,092 | 66 | $19.56 | $21K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,068 | 433 | $11.96 | $13K |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 697 | 11 | $2.72 | $1,894 |
| 99214 Office E&M - Established | Office | 604 | 303 | $90.54 | $55K |
| J1750 Injection, iron dextran, 50 mg | Office | 593 | 29 | $13.06 | $7,747 |
| 99232 Hospital E&M - Subsequent | Facility | 555 | 109 | $58.59 | $33K |
| 99233 Hospital E&M - Subsequent | Facility | 538 | 118 | $81.54 | $44K |
| 96413 Chemotherapy Administration | Office | 491 | 71 | $89.38 | $44K |
| 96365 Intravenous Infusion, Hydration | Office | 464 | 67 | $44.12 | $20K |
By year: 2022 $2.1M for 105,129 services; 2023 $2.2M for 121,004 services; 2024 $2.1M for 90,665 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,526 | 544 | $8.58 | $22K |
| 85027 Blood Count | 2,447 | 536 | $6.11 | $15K |
| 85610 Clinical Chemistry | 119 | 15 | $4.20 | $500 |
| 80053 Clinical Chemistry | 110 | 16 | $9.26 | $1,019 |
| 85025 Blood Count | 23 | 23 | $7.61 | $175 |
Medicare prescription drug claims, 2024
In 2024, the drug Rohit Kapoor prescribed most often to Medicare patients was Keytruda (Pembrolizumab), with 141 prescriptions and refills. In total Rohit Kapoor wrote 2,316 Medicare prescriptions that cost $10.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Keytruda Pembrolizumab | 141 | 141 | 17 | $1.7M |
| Eliquis Apixaban | 111 | 149 | 23 | $85K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 96 | 96 | 35 | $4,022 |
| Anastrozole Generic | 78 | 223 | 28 | $1,181 |
| Ondansetron Hcl Generic | 75 | 75 | 42 | $722 |
| Opdivo Nivolumab | 59 | 59 | Under 11 | $813K |
| Warfarin Sodium Generic | 58 | 119 | 12 | $697 |
| Cyclophosphamide Generic | 56 | 56 | Under 11 | $28K |
| Prednisone Generic | 56 | 58 | 22 | $269 |
| Padcev Enfortumab Vedotin-Ejfv | 52 | 52 | Under 11 | $1.7M |
| Xarelto Rivaroxaban | 51 | 91 | 14 | $49K |
| Neulasta Pegfilgrastim | 47 | 47 | Under 11 | $440K |
| Dexamethasone Generic | 44 | 52 | 13 | $485 |
| Pemetrexed Disodium Generic | 43 | 43 | Under 11 | $7,948 |
| Ondansetron Odt Ondansetron | 42 | 42 | 23 | $356 |
Brand drugs: 1,021 claims; generic drugs: 1,295 claims; opioid claims: 141.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rohit Kapoor $7,584 ($7,584 in general payments such as food, travel and fees) from 50 companies. The largest payer was Astellas Pharma US Inc with $1,924.
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc 4503.T | 7 | $1,924 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $1,307 |
| Janssen Biotech, Inc. JNJ | 25 | $511 |
| Pfizer Inc. PFE | 16 | $321 |
| Merck Sharp & Dohme LLC MRK | 10 | $239 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $211 |
| Genzyme Corporation SNY | 8 | $206 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $175 |
| Incyte Corporation INCY | 8 | $166 |
| Sobi, Inc SOBI.ST | 5 | $166 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.